Compare DexCom, Inc. (DXCM) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Phillips 66 — how do they compare? DexCom, Inc. trades at $77.8 (market cap $28.06B), while Phillips 66 trades at $202.1 (market cap $78.65B). The key difference: Phillips 66 is far larger — about 2.8× DexCom, Inc.'s market cap, and Phillips 66 pays a 2.59% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | PSX | |
|---|---|---|
Market Cap | $28.06B | $78.65B |
Sector | Health | Energy |
52-Week High | $89.53 | $201.45 |
52-Week Low | $54.84 | $118.37 |
Enterprise Value | $27.03B | $100.62B |
Dividend Yield | — | 2.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Phillips 66 (PSX) trades at $201.45, up 1.59% on the day, with a bullish technical signal and strong analyst support. The stock has beaten earnings estimates for the last three quarters, though revenue has declined from $170.0B in 2022 to $132.4B in 2025 (SEC filings, 2025). Valuation ratios appear reasonable with a P/E of 19.38 and P/S of 0.59, while recent news highlights refining strength and dividend consistency.
The outlook remains positive given robust refining margins and a diversified business model, but risks include volatile energy markets and declining revenue trends. With 57% of analysts rating it a Buy and a consensus price target of $201.50 (MarketBeat, July 2026), the stock offers value with income potential, though investors should weigh execution risks against sector tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
